BofA Securities initiated coverage on TG Therapeutics with a new price target
$TGTX
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities initiated coverage of TG Therapeutics with a rating of Underperform and set a new price target of $5.00